The adenomyosis/endometriosis IVF patient – call for clinical focus
Reproductive BioMedicine Online · 2024
DOI: 10.1016/j.rbmo.2023.103737 ↗Kurz gefasst
Fachartikel in der Zeitschrift Reproductive BioMedicine Online, 2024. Verfasst von Mauro Cozzolino und 4 weiteren Autor:innen. Beteiligte Einrichtung: IVIRMA Global Research Alliance, IVI Roma, Rome, Italy.; IVIRMA Global Research Alliance, IVI Foundation-IIS la Fe, Valencia, Spain.. Electronic addr…. Hauptthemen laut MEDLINE: Endometriosis, Adenomyosis, Uterine Diseases. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Endometriosis and adenomyosis are distinct clinical conditions that carry the same pathophysiological features. In recent years the clinical focus on assisted reproductive technology patients with either condition (E/A) has increased, in the recognition that this subgroup of patients might need special attention to obtain reproductive success. Endometriosis and adenomyosis are characterized by a disruption of progesterone and oestrogen signalling pathways, resulting in local oestrogen dominance and progesterone resistance at the receptor level. Recent scientific evidence suggests that the endometrial progesterone receptor resistance encountered in E/A patients can be overcome by a freeze-all policy, followed by down-regulating circulating oestradiol concentrations prior to frozen embryo transfer (FET), in combination with an increase in exogenous luteal phase progesterone supplementation in hormonal replacement therapy (HRT) FET cycles. Specifically, for adenomyosis patients who do not respond to gonadotrophin-releasing hormone agonist down-regulation in terms of a decrease in circulating oestradiol concentrations, a small case series has suggested that the addition of an aromatase inhibitor for 21 days prior to HRT-FET is a valid option. Endometriosis and adenomyosis are hormonally active diseases, which need to be treated by controlling local hyperoestrogenism and progesterone resistance. Based on physiology and recent preliminary clinical data, the authors of this opinion paper wish to stimulate discussion and spark interest in research in E/A patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IVIRMA Global Research Alliance, IVI Roma, Rome, Italy.; IVIRMA Global Research Alliance, IVI Foundation-IIS la Fe, Valencia, Spain.. Electronic address: mauro.cozzolino@ivirma.com.
- The Fertility Clinic, Skive Regional Hospital, Denmark and Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
- IVIRMA Global Research Alliance, IVI Roma, Rome, Italy.; IVIRMA Global Research Alliance, IVI Foundation-IIS la Fe, Valencia, Spain.
- IVIRMA Global Research Alliance, IVI, Madrid, Spain.; Department of Obstetrics and Gynecology, Universidad Rey Juan Carlos, Madrid, Spain.
Zitieren
APA
Cozzolino, M., Alsbjerg, B., Pellicer, A., Garcia-Velasco, J. A., & Humaidan, P. (2024). The adenomyosis/endometriosis IVF patient – call for clinical focus. Reproductive BioMedicine Online. https://doi.org/10.1016/j.rbmo.2023.103737
Vancouver
Cozzolino M, Alsbjerg B, Pellicer A, Garcia-Velasco JA, Humaidan P. The adenomyosis/endometriosis IVF patient – call for clinical focus. Reproductive BioMedicine Online. 2024. doi:10.1016/j.rbmo.2023.103737
BibTeX
@article{Cozzolino2024,
author = {Cozzolino, Mauro and Alsbjerg, Birgit and Pellicer, Antonio and Garcia-Velasco, Juan Antonio and Humaidan, Peter},
title = {The adenomyosis/endometriosis IVF patient – call for clinical focus},
journal = {Reproductive BioMedicine Online},
year = {2024},
doi = {10.1016/j.rbmo.2023.103737}
}
EUVIMED